Basic Research
Copyright ©2005 Baishideng Publishing Group Inc.
World J Gastroenterol. May 14, 2005; 11(18): 2744-2747
Published online May 14, 2005. doi: 10.3748/wjg.v11.i18.2744
Table 1 pBcl-2 and pBax expression and their relationship with clinicopathological parameters for the patients with pancreatic cancer.
ParameterNo. of patientsNumber of pBcl-2 and pBax expressing (%)
pBcl-2 (+)pBcl-2 (-)PBax (+)PBax (-)
Overall5921 (35.6)38 (64.4)29 (49.2)30 (50.8)
Age (yr)<654717 (36.2)30 (63.8)26 (55.3)21 (44.7)
≥65124 (33.3)8 (66.7)3 (25)9 (75)
GenderMale3814 (36.8)24 (63.2)18 (47.3)20 (52.7)
Female217 (33.3)14 (66.7)11 (52.4)10 (47.6)
TNM stageI41 (25)3 (75)3 (75)1 (25)
II85 (62.5)3 (37.5)4 (50)4 (50)
III4214 (33.3)28 (66.7)19 (45.2)23 (54.8)
IV51 (20)4 (80)3 (60)2 (40)
GradeWell198 (42.1)11 (57.9)11 (57.9)8 (42.1)
Moderate218 (38.1)13 (61.9)8 (38.1)13 (61.9)
Poor195 (26.3)14 (73.7)10 (52.6)9 (47.7)
Table 2 Correlation between various factors and survival time by Cox proportional hazards model (dependent variable, mo; censoring variable, death due to pancreatic cancer).
VariableParameter estimate (SE)Conditional risk ratio (95% CI)P2)
Overall pBcl-2-1.216 (0.340)0.297 (0.152-0.577)0.001
(n = 59) TNM0.582 (0.246)1.790 (1.104-2.902)0.018
Age (yr)0.037 (0.017)1.038 (1.004-1.073)0.026
pBax0.734 (0.360)2.084 (1.029-4.222)0.041
Site-0.566 (0.487)0.568 (0.219-1.474)0.245
Grade0.169 (0.268)1.184 (0.701-2.001)0.528
Gender0.061 (0.352)1.063 (0.534-2.118)0.862